PWWP2B

Summary

PWWP2B (PWWP domain containing 2B, HGNC:25150) is a protein-coding gene on chromosome 10q26.3, encoding PWWP domain-containing protein 2B (Q6NUJ5). Chromatin-binding protein that acts as an adapter between distinct nucleosome components (H3K36me3 or H2A.Z) and chromatin-modifying complexes, contributing to the regulation of the levels of histone acetylation at actively transcribed genes.

Enables NuRD complex binding activity. Predicted to be involved in chromatin remodeling; positive regulation of transcription elongation by RNA polymerase II; and regulation of cold-induced thermogenesis. Located in nucleoplasm.

Source: NCBI Gene 170394 — RefSeq curated summary.

At a glance

• GWAS associations: 1
• Clinical variants (ClinVar): 136 total
• Druggable target: yes — 1 molecules with ChEMBL bioactivity
• MANE Select transcript: NM_138499

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:25150
Approved symbol	PWWP2B
Name	PWWP domain containing 2B
Location	10q26.3
Locus type	gene with protein product
Status	Approved
Aliases	bA432J24.1, FLJ46823
Ensembl gene	ENSG00000171813
Ensembl biotype	protein_coding
Entrez	170394

Gene structure

Transcript identifiers

Ensembl transcripts: 4 — 4 protein_coding

ENST00000305233, ENST00000631148, ENST00000856284, ENST00000962282

RefSeq mRNA: 2 — MANE Select: NM_138499 NM_001098637, NM_138499

CCDS: CCDS44497, CCDS7667

Canonical transcript exons

ENST00000305233 — 3 exons

Exon	Start	End
ENSE00001611851	132417061	132417859
ENSE00001676363	132404626	132406289
ENSE00003845279	132397200	132397351

Expression profiles

Bgee: expression breadth ubiquitous, 240 present calls, max score 98.99.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 3.6454 / max 488.4674, expressed in 1156 samples.

FANTOM5 promoters (4 alternative TSS)

Promoter ID	TPM avg	Samples expressed
107711	1.8346	833
107716	1.4179	568
107715	0.3602	132
107712	0.0326	8

Top tissues by expression

250 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
pancreatic ductal cell	CL:0002079	98.99	silver quality
mucosa of transverse colon	UBERON:0004991	92.95	gold quality
amniotic fluid	UBERON:0000173	92.36	gold quality
lower esophagus mucosa	UBERON:0035834	92.32	gold quality
kidney epithelium	UBERON:0004819	92.11	gold quality
nasal cavity epithelium	UBERON:0005384	90.45	silver quality
right adrenal gland	UBERON:0001233	89.14	gold quality
right adrenal gland cortex	UBERON:0035827	88.74	gold quality
adrenal cortex	UBERON:0001235	88.54	gold quality
left adrenal gland	UBERON:0001234	88.53	gold quality
body of pancreas	UBERON:0001150	88.50	gold quality
cerebellar vermis	UBERON:0004720	88.45	gold quality
left adrenal gland cortex	UBERON:0035825	88.27	gold quality
vena cava	UBERON:0004087	87.51	gold quality
parotid gland	UBERON:0001831	87.32	gold quality
hindlimb stylopod muscle	UBERON:0004252	86.71	gold quality
ileal mucosa	UBERON:0000331	86.68	gold quality
putamen	UBERON:0001874	86.50	gold quality
spleen	UBERON:0002106	86.44	gold quality
apex of heart	UBERON:0002098	86.41	gold quality
adrenal gland	UBERON:0002369	86.38	gold quality
gastrocnemius	UBERON:0001388	86.15	gold quality
nucleus accumbens	UBERON:0001882	86.15	gold quality
left ventricle myocardium	UBERON:0006566	86.00	gold quality
heart right ventricle	UBERON:0002080	85.47	silver quality
transverse colon	UBERON:0001157	85.31	gold quality
olfactory segment of nasal mucosa	UBERON:0005386	85.17	gold quality
caudate nucleus	UBERON:0001873	84.88	gold quality
muscle of leg	UBERON:0001383	84.77	gold quality
body of tongue	UBERON:0011876	84.77	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-ANND-3	yes	6.29

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

23 targeting PWWP2B, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-4481	100.00	66.42	1669
HSA-MIR-497-5P	99.92	71.83	2674
HSA-MIR-627-3P	99.90	71.42	3316
HSA-MIR-15A-5P	99.90	72.80	2787
HSA-MIR-15B-5P	99.90	72.78	2798
HSA-MIR-16-5P	99.90	72.80	2780
HSA-MIR-195-5P	99.90	72.81	2805
HSA-MIR-424-5P	99.89	71.90	2641
HSA-MIR-6838-5P	99.89	71.94	2690
HSA-MIR-3609	99.52	69.89	2587
HSA-MIR-548AH-5P	99.52	69.73	2626
HSA-MIR-6839-3P	99.39	68.86	1301
HSA-MIR-3125	99.14	68.49	2269
HSA-MIR-4504	99.10	69.14	1328
HSA-MIR-3916	98.99	68.04	2155
HSA-MIR-6859-5P	98.99	68.07	2049
HSA-MIR-583	98.71	67.44	1791
HSA-MIR-5187-5P	98.54	67.94	952
HSA-MIR-3661	97.83	67.30	705
HSA-MIR-3665	97.73	65.08	975
HSA-MIR-631	97.05	66.93	602
HSA-MIR-6767-3P	93.99	66.01	204
HSA-MIR-6812-3P	90.58	63.80	60

Literature-anchored findings (GeneRIF, showing 2)

• Study in HeLa, HEK293F, and mouse embryonic stem cells reveal that loss of PWWP2A/B leads to increases in histone acetylation predominantly at highly expressed genes, accompanied by decreases in Pol II elongation. Collectively, these findings suggest a role for PWWP2A/B in regulating transcription through the fine-tuning of histone acetylation dynamics at actively transcribed genes. (PMID:30228260)
• PWWP2B promotes DNA end resection and homologous recombination. (PMID:35582821)

Cross-species orthologs

3 orthologs

Organism	Symbol	Gene ID
danio_rerio	pwwp2b	ENSDARG00000101080
mus_musculus	Pwwp2b	ENSMUSG00000060260
rattus_norvegicus	Pwwp2b	ENSRNOG00000036649

Paralogs (4): DNMT3B (ENSG00000088305), DNMT3A (ENSG00000119772), DNMT3L (ENSG00000142182), PWWP2A (ENSG00000170234)

Protein

Protein identifiers

PWWP domain-containing protein 2B — Q6NUJ5 (reviewed: Q6NUJ5)

All UniProt accessions (1): Q6NUJ5

UniProt curated annotations — full annotation on UniProt →

Function. Chromatin-binding protein that acts as an adapter between distinct nucleosome components (H3K36me3 or H2A.Z) and chromatin-modifying complexes, contributing to the regulation of the levels of histone acetylation at actively transcribed genes. Competes with CHD4 and MBD3 for interaction with MTA1 to form a NuRD subcomplex, preventing the formation of full NuRD complex (containing CHD4 and MBD3), leading to recruitment of HDACs to gene promoters resulting in turn in the deacetylation of nearby H3K27 and H2A.Z. Plays a role in facilitating transcriptional elongation through regulation of histone acetylation. Negatively regulates brown adipocyte thermogenesis by interacting with and stabilizing HDAC1 at the UCP1 gene promoter, thereby promoting histone deacetylation at the promoter leading to the repression of UCP1 expression.

Subunit / interactions. Component of a MTA1-specific subcomplex of the NuRD complex composed of PWWP2B, MTA1 and HDAC1 but does not contain CHD4 and MBD3. Interacts with MTA1 and HDAC1. Interacts with MTA2, MTA3, HDAC2, RBBP4, RBBP7, BRCC3 and ZNF516. Does not interact with CHD4 and MBD3.

Post-translational modifications. Deubiquitinated by BRCC3; leading to its stabilization.

Isoforms (2)

UniProt ID	Names	Canonical?
Q6NUJ5-1	1	yes
Q6NUJ5-2	2

RefSeq proteins (2): NP_001092107, NP_612508* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR000313	PWWP_dom	Domain
IPR050390	C5-Methyltransferase	Family

Pfam: PF00855

UniProt features (33 total): strand 8, modified residue 5, region of interest 4, helix 4, compositionally biased region 4, splice variant 2, sequence variant 2, turn 2, chain 1, domain 1

Structure

Experimental structures (PDB)

1 structures.

PDB	Method	Resolution (Å)
4LD6	X-RAY DIFFRACTION	1.7

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q6NUJ5-F1	60.71	0.15

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Post-translational modifications (5): 84, 186, 206, 250, 447

Function

Pathways and Gene Ontology

Reactome pathways

1 pathways

ID	Pathway
R-HSA-9937850	NuRD complex assembly

MSigDB gene sets: 93 (showing top): ZHAN_MULTIPLE_MYELOMA_PR_DN, CHANDRAN_METASTASIS_DN, GATA6_01, LIAO_METASTASIS, ZHOU_INFLAMMATORY_RESPONSE_LIVE_DN, AACTTT_UNKNOWN, GOBP_MULTICELLULAR_ORGANISMAL_LEVEL_HOMEOSTASIS, HAND1E47_01, DOUGLAS_BMI1_TARGETS_UP, YY1_01, GOBP_CHROMATIN_REMODELING, GOBP_TEMPERATURE_HOMEOSTASIS, GOBP_POSITIVE_REGULATION_OF_DNA_TEMPLATED_TRANSCRIPTION_ELONGATION, GOBP_REGULATION_OF_DNA_TEMPLATED_TRANSCRIPTION_ELONGATION, CHARAFE_BREAST_CANCER_LUMINAL_VS_MESENCHYMAL_UP

GO Biological Process (3): chromatin remodeling (GO:0006338), positive regulation of transcription elongation by RNA polymerase II (GO:0032968), regulation of cold-induced thermogenesis (GO:0120161)

GO Molecular Function (2): NuRD complex binding (GO:0120325), protein binding (GO:0005515)

GO Cellular Component (2): nucleus (GO:0005634), nucleoplasm (GO:0005654)

Reactome top-level categories

Rollup of top-1 pathways:

Category	Pathways
CHD3, CHD4, CHD5 subfamily	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
chromatin organization	1
transcription elongation by RNA polymerase II	1
positive regulation of DNA-templated transcription, elongation	1
regulation of transcription elongation by RNA polymerase II	1
positive regulation of transcription by RNA polymerase II	1
regulation of multicellular organismal process	1
cold-induced thermogenesis	1
protein-containing complex binding	1
binding	1
intracellular membrane-bounded organelle	1
nuclear lumen	1
cellular anatomical structure	1

Protein interactions and networks

STRING

304 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
PWWP2B	LYSET	Q8N6I4	607
PWWP2B	RBBP4	P31149	603
PWWP2B	ASB12	Q8WXK4	549
PWWP2B	RBM12	Q9NTZ6	512
PWWP2B	TAF5L	O75529	488
PWWP2B	C2orf68	Q2NKX9	474
PWWP2B	ATP8B2	P98198	469
PWWP2B	ZMYM2	Q9UBW7	449
PWWP2B	KRTAP4-8	Q9BYQ9	444
PWWP2B	PPEF1	O14829	440
PWWP2B	RLIM	Q9NVW2	436
PWWP2B	BRD4	O60885	421
PWWP2B	HDGFL1	Q5TGJ6	420
PWWP2B	GPR101	Q96P66	403
PWWP2B	NSD3	Q9BZ95	399

IntAct

20 interactions, top by confidence:

A	B	Type	Score
HDAC1	CDK2AP1	psi-mi:“MI:0914”(association)	0.840
HDAC1	TNRC18	psi-mi:“MI:0914”(association)	0.790
RBBP4	CDK2AP1	psi-mi:“MI:0914”(association)	0.790
P4HA3	FAM171A2	psi-mi:“MI:0914”(association)	0.640
PSMA3	PWWP2B	psi-mi:“MI:0915”(physical association)	0.560
PWWP2B	PSMA3	psi-mi:“MI:0915”(physical association)	0.560
GOLGA6L9	PWWP2B	psi-mi:“MI:0915”(physical association)	0.560
PWWP2B	ABI2	psi-mi:“MI:0915”(physical association)	0.560
RBBP4	TNRC18	psi-mi:“MI:0914”(association)	0.530
RBBP7	EPOP	psi-mi:“MI:0914”(association)	0.530
PWWP2B	PRKDC	psi-mi:“MI:0915”(physical association)	0.400
BRD2	POLR2B	psi-mi:“MI:0914”(association)	0.350
PNMA8A	AP3B1	psi-mi:“MI:0914”(association)	0.350
PWWP2B	GOLGA6L9	psi-mi:“MI:0915”(physical association)	0.000
PWWP2B	ABI2	psi-mi:“MI:0915”(physical association)	0.000

BioGRID (23): PWWP2B (Two-hybrid), PWWP2B (Affinity Capture-MS), PWWP2B (Affinity Capture-MS), PWWP2B (Affinity Capture-MS), PWWP2B (Affinity Capture-MS), PWWP2B (Affinity Capture-RNA), PWWP2B (Two-hybrid), GOLGA6L9 (Two-hybrid), PWWP2B (Proximity Label-MS), PWWP2B (Affinity Capture-MS), PWWP2B (Affinity Capture-MS), PWWP2B (Affinity Capture-MS), PWWP2B (Affinity Capture-MS), PWWP2B (Affinity Capture-MS), PWWP2B (Affinity Capture-MS)

ESM2 similar proteins: A0JNJ4, A4IHR5, A6H7J1, A7UKY7, D4AE48, E9Q9M8, O15209, O35615, O75081, O95785, P03966, P04198, P39881, P49796, P52746, Q01101, Q1LY51, Q29RS4, Q32KV8, Q4KLY2, Q505G8, Q5T6C5, Q5TJE2, Q61976, Q62511, Q63379, Q63ZV0, Q6AY75, Q6NUJ5, Q6NV74, Q6P0F9, Q7T3H2, Q8BG80, Q8CDC7, Q8CE64, Q8IX07, Q8N554, Q8R4U1, Q96C00, Q96JP5

Diamond homologs: A0A1L8GR68, E9Q9M8, F7AQ22, O88508, Q1LZ53, Q4W5Z4, Q69Z61, Q6NUJ5, Q96N64, Q9FNE4, Q9UBC3, Q9Y6K1, O88509, Q923W4, Q9JMG7, Q9Y3E1, P00476, P09915, P0DOY1, P34906, Q10SU5, Q1LZ50, Q2RBJ4, Q9CWR8, Q9LXE5, Q9M548, Q9UJW3, Q9MA56, A4FUF0, F4IN78, F4IZM8, O75475, P51858, P51859, Q175F8, Q29NG1, Q32N87, Q3UMU9, Q49A26, Q562D5

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

136 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	118
Likely benign	10
Benign	0

Top pathogenic / likely-pathogenic (0)

SpliceAI

1002 predictions. Top by Δscore:

Variant	Effect	Δscore
10:132397352:G:GG	donor_gain	1.0000
10:132404618:ATT:A	acceptor_gain	1.0000
10:132404623:CAG:C	acceptor_loss	1.0000
10:132404625:G:A	acceptor_loss	1.0000
10:132397348:AAAAG:A	donor_loss	0.9900
10:132397350:AA:A	donor_gain	0.9900
10:132397350:AAG:A	donor_loss	0.9900
10:132397351:AGT:A	donor_loss	0.9900
10:132397352:GTGA:G	donor_loss	0.9900
10:132397353:T:G	donor_loss	0.9900
10:132397354:GA:G	donor_loss	0.9900
10:132404618:A:AG	acceptor_gain	0.9900
10:132404620:T:TA	acceptor_gain	0.9900
10:132404624:A:AG	acceptor_gain	0.9900
10:132404625:G:GC	acceptor_gain	0.9900
10:132404625:GGT:G	acceptor_gain	0.9900
10:132404625:GGTCC:G	acceptor_gain	0.9900
10:132417055:CCCAA:C	acceptor_loss	0.9900
10:132417056:CCAA:C	acceptor_loss	0.9900
10:132417057:CAAGG:C	acceptor_loss	0.9900
10:132417058:AAGG:A	acceptor_loss	0.9900
10:132417059:A:AG	acceptor_loss	0.9900
10:132417059:A:G	acceptor_gain	0.9900
10:132417060:G:GC	acceptor_loss	0.9900
10:132397349:AAA:A	donor_gain	0.9800
10:132404619:T:G	acceptor_gain	0.9800
10:132417058:A:AG	acceptor_gain	0.9800
10:132397292:G:GA	donor_gain	0.9700
10:132417047:T:A	acceptor_loss	0.9700
10:132417060:G:GG	acceptor_gain	0.9700

AlphaMissense

3781 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
10:132405981:T:A	V494D	1.000
10:132405983:T:A	W495R	1.000
10:132405983:T:C	W495R	1.000
10:132405264:T:C	I255T	0.999
10:132405985:G:C	W495C	0.999
10:132405985:G:T	W495C	0.999
10:132406010:T:A	W504R	0.999
10:132406010:T:C	W504R	0.999
10:132406014:C:A	P505Q	0.999
10:132406023:T:A	V508D	0.999
10:132406088:T:A	W530R	0.999
10:132406088:T:C	W530R	0.999
10:132405264:T:G	I255S	0.998
10:132406012:G:C	W504C	0.998
10:132406012:G:T	W504C	0.998
10:132406013:C:T	P505S	0.998
10:132406083:T:A	V528D	0.998
10:132406090:G:C	W530C	0.998
10:132406090:G:T	W530C	0.998
10:132406091:T:C	F531L	0.998
10:132406093:T:A	F531L	0.998
10:132406093:T:G	F531L	0.998
10:132397326:G:T	G34W	0.997
10:132405306:T:C	I269T	0.997
10:132405972:G:T	G491V	0.997
10:132405984:G:C	W495S	0.997
10:132406001:T:C	F501L	0.997
10:132406003:T:A	F501L	0.997
10:132406003:T:G	F501L	0.997
10:132406007:T:A	W503R	0.997

dbSNP variants (sampled 300 via entrez): RS1000007315 (10:132405579 A>C), RS1000097449 (10:132405591 G>C), RS1000148235 (10:132410257 G>C), RS1000314373 (10:132396401 G>T), RS1000343746 (10:132397741 G>A), RS1000519981 (10:132410047 G>A,T), RS1000554207 (10:132405776 G>A), RS1000750152 (10:132413138 TCAA>T), RS1000795797 (10:132414288 A>G), RS1000870701 (10:132399043 A>C,G), RS1000918060 (10:132416874 C>G), RS1000942274 (10:132396866 G>C), RS1001041057 (10:132397601 G>A,T), RS1001123173 (10:132408953 T>C), RS1001163504 (10:132417234 C>A,G,T)

Disease associations

OMIM: gene `` | disease phenotypes:

GenCC curated gene-disease

Mondo (0):

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

1 associations (top):

Study	Trait	p-value
GCST012048_13	Triglyceride levels	8.000000e-07

EFO canonical traits (1, from GWAS)

EFO ID	Trait name
EFO:0004530	triglyceride measurement

Drugs & pharmacology

Drug and pharmacology data

Is drug target: yes

ChEMBL targets (1): CHEMBL6066163 (SINGLE PROTEIN)

Molecules with ChEMBL bioactivity

1 molecules (phase ≥1), by development phase (incl. off-target/promiscuous compounds). Patent mentions across the top 20 by phase: 1,538 (via chembl_molecule»patent_compound — counts attach to the compound, not the gene–compound relationship, so off-target/promiscuous molecules can dominate).

Molecule	Name	Phase	Patents
CHEMBL1232461	MOLIBRESIB	2	1,538

PharmGKB: 1 entry (VIP=true, CPIC=false)

ChEMBL bioactivities

2 potent at pChembl≥5 of 2 total, top 2 by pChembl (potency: 10 = 0.1 nM, 6 = 1 µM).

pChembl	Type	Value	Unit	Molecule
7.60	Kd	25	nM	MOLIBRESIB
7.40	IC50	40	nM	MOLIBRESIB

PubChem BioAssay actives

2 with measured affinity, of 7 total; 1 most potent distinct compounds. Largely complementary to BindingDB; screening values are coarse (µM, 4 dp), so sub-nM hits tie at the floor.

Compound	Assay	Type	Value	Unit
2-[(4S)-6-(4-chlorophenyl)-8-methoxy-1-methyl-4H-[1,2,4]triazolo[4,3-a][1,4]benzodiazepin-4-yl]-N-ethylacetamide	2179188: Binding affinity against PWWP2B (unknown origin) assessed as apparent dissociation constant incubated for 1 hr by colloidal coomassie staining based LC-MS/MS analysis	kd	0.0250	uM

CTD chemical–gene interactions

32 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Valproic Acid	affects cotreatment, increases expression, increases methylation	6
trichostatin A	affects cotreatment, increases expression	3
mercuric bromide	increases expression, affects cotreatment	2
Phenylmercuric Acetate	affects cotreatment, increases expression	2
p-Chloromercuribenzoic Acid	increases expression, affects cotreatment	2
aristolochic acid I	increases expression	1
GSK-J4	increases expression	1
FR900359	affects phosphorylation	1
methylmercuric chloride	increases expression	1
methyleugenol	increases expression	1
ethyl-p-hydroxybenzoate	increases expression	1
11-nor-delta(9)-tetrahydrocannabinol-9-carboxylic acid	increases abundance, affects methylation	1
cobaltous chloride	increases expression	1
aflatoxin B2	decreases methylation	1
beta-methylcholine	affects expression	1
di-n-butylphosphoric acid	affects expression	1
4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	affects cotreatment, increases expression	1
dorsomorphin	affects cotreatment, increases expression	1
(+)-JQ1 compound	decreases expression	1
4-(4-((5-(4,5-dimethyl-2-nitrophenyl)-2-furanyl)methylene)-4,5-dihydro-3-methyl-5-oxo-1H-pyrazol-1-yl)benzoic acid	decreases expression	1
Panobinostat	increases expression, affects cotreatment	1
Benzo(a)pyrene	affects methylation	1
Caffeine	decreases phosphorylation	1
Cannabinoids	affects methylation, increases abundance	1
Cisplatin	decreases expression	1
Diethylhexyl Phthalate	increases expression	1
Doxorubicin	decreases expression	1
Estradiol	affects cotreatment, decreases expression	1
Smoke	decreases expression	1
Tretinoin	decreases expression	1

ChEMBL screening assays

7 unique, capped per target: 7 binding

Representative assays (with source publication via chembl_document):

Assay ID	Type	Description	Source paper
CHEMBL5697380	Binding	Inhibition of PWWP2B (unknown origin) assessed as fold change at 10 uM incubated for 1 hr by colloidal coomassie staining based LC-MS/MS analysis	Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemia. — Nature

Cellosaurus cell lines

2 cell lines: 2 cancer cell line

First 10 cell lines (id-ordered, not curated):

Cellosaurus	Name	Category	Sex
CVCL_TH78	HAP1 PWWP2B (-) 1	Cancer cell line	Male
CVCL_TH79	HAP1 PWWP2B (-) 2	Cancer cell line	Male

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.